S&P ASX All Technology

US Dollar vs AUD

Register for real-time alerts, custom portfolio, and market movers

Get Started

AXSM Axsome Therapeutics Inc

68.81

0.60 (0.88%)

After Hours

Last Updated: 07:39:24

Delayed by 15 minutes

Axsome Therapeutics EPS beats by $0.03

To read the full story on Seeking Alpha, click here.

Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
From Mar 2024 to Apr 2024

Click Here for more Axsome Therapeutics Charts.

Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
From Apr 2023 to Apr 2024

Click Here for more Axsome Therapeutics Charts.

Axsome Therapeutics Inc News

Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
Monday 15 April 2024 (1 day ago) • GlobeNewswire Inc.

Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
Wednesday 10 April 2024 (6 days ago) • GlobeNewswire Inc.

Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
Monday 1 April 2024 (2 weeks ago) • GlobeNewswire Inc.

Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
Monday 25 March 2024 (3 weeks ago) • GlobeNewswire Inc.

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
Monday 25 March 2024 (3 weeks ago) • GlobeNewswire Inc.

Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
Tuesday 19 March 2024 (4 weeks ago) • GlobeNewswire Inc.

Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
Tuesday 5 March 2024 (1 month ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Friday 1 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 1 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 1 March 2024 (2 months ago) • Edgar (US Regulatory)

Axsome Therapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
Tuesday 27 February 2024 (2 months ago) • GlobeNewswire Inc.

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Saturday 24 February 2024 (2 months ago) • Edgar (US Regulatory)

More Axsome Therapeutics Inc News Articles

Westpac Banking

JP Morgan Chase

National Australia Bank

Woodside Petroleum

S&P ASX 300 Metals and M...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions